Research grant
Galantos Pharma, a German company set up on the basis of research at the University of Mainz and the University of Vienna, has won a grant of €360,000 from Investitions- und Strukturbank Rheinland-Pfalz (ISB) GmbH, the investment and economic development bank of
the German federal state of Rheinland-Pfalz to develop its technology platform for combatting Alzheimer’s disease.
“The funds will allow us to expand our technology platform for the optimisation of compounds targeting nicotinic acetylcholine receptors with subunit specificity and selectivity against muscarinic acetylcholine receptors“, said Dr Andreas Köpke, managing director and CBO of Galantos Pharma. “These compounds have considerable use in Alzheimer’s disease and other psychiatric indications.”
Galantos was founded in 2005 by Alfred Maelicke in Mainz and Ulrich Jordis in Vienna, after they obtained a patent on the basis of their investigations into galantamine, a natural compound that reduces cognitive impairment in Alzheimer’s disease. The company is based at the Technology Centre Mainz.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
